newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000

41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the